Endo Sweats On Vasostrict Competition While Varenicline Is A Boon
Sterile Injectable Unit Impaired By Hundreds Of Millions Of Dollars
Endo management turned talk once again to its expectations for Vasostrict competition in the coming months during its year-end earnings call. The US-based firm enjoyed a better end to the year as it capitalized on the opportunity for shortage-hit varenicline.
